Abstract P1-13-08: A prospective non-randomized clinical trial of adjuvant carboplatin chemotherapy in triple negative breast cancer

Mapping Intimacies ◽

10.1158/1538-7445.sabcs18-p1-13-08 ◽

2019 ◽

Author(s):

C Hamm ◽

S Kulkarni ◽

R Gupta ◽

J Mathews ◽

K Amin ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Randomized Clinical Trial ◽

Triple Negative Breast Cancer ◽

Triple Negative

Download Full-text

Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00

Breast Cancer Research and Treatment ◽

10.1007/s10549-016-3863-3 ◽

2016 ◽

Vol 158 (2) ◽

pp. 323-331 ◽

Author(s):

Giancarlo Pruneri ◽

Kathryn P. Gray ◽

Andrea Vingiani ◽

Giuseppe Viale ◽

Giuseppe Curigliano ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Randomized Clinical Trial ◽

Prognostic Marker ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Tumor Infiltrating Lymphocytes ◽

Phase Iii ◽

Infiltrating Lymphocytes

Download Full-text

Faculty Opinions recommendation of Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.738493485.793578017 ◽

2020 ◽

Author(s):

Maxine Gossell-Williams

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Randomized Clinical Trial ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Download Full-text

2O Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): Analysis of the GeparSixto randomized clinical trial

Annals of Oncology ◽

10.1016/j.annonc.2021.03.016 ◽

2021 ◽

Vol 32 ◽

pp. S22

Author(s):

A. Llop-Guevara ◽

V. Vladimirova ◽

A. Schneeweiss ◽

G. Villacampa ◽

T. Karn ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Homologous Recombination ◽

Randomized Clinical Trial ◽

Clinical Outcomes ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Homologous Recombination Deficiency

Download Full-text

Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial

Annals of Oncology ◽

10.1016/j.annonc.2021.09.003 ◽

2021 ◽

Author(s):

A. Llop-Guevara ◽

S. Loibl ◽

G. Villacampa ◽

V. Vladimirova ◽

A. Schneeweiss ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Homologous Recombination ◽

Randomized Clinical Trial ◽

Clinical Outcomes ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Homologous Recombination Deficiency

Download Full-text

Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-021-06307-3 ◽

2021 ◽

Author(s):

Foluso O. Ademuyiwa ◽

Ina Chen ◽

Jingqin Luo ◽

Mothaffar F. Rimawi ◽

Ian S. Hagemann ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Pathological Response

Download Full-text

Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

JAMA Oncology ◽

10.1001/jamaoncol.2019.1029 ◽

2019 ◽

Vol 5 (8) ◽

pp. 1132 ◽

Author(s):

Shaveta Vinayak ◽

Sara M. Tolaney ◽

Lee Schwartzberg ◽

Monica Mita ◽

Georgia McCann ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Download Full-text

Abstract OT1-05-02: A phase II clinical trial of the combination of pembrolizumab and selective androgen receptor modulator GTx-024 in patients with advanced androgen receptor positive triple negative breast cancer

10.1158/1538-7445.sabcs17-ot1-05-02 ◽

2018 ◽

Author(s):

Y Yuan ◽

P Frankel ◽

T Synold ◽

P Lee ◽

S Yost ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Androgen Receptor ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Clinical Trial ◽

Selective Androgen Receptor Modulator ◽

Receptor Modulator

Download Full-text

Abstract PD6-07: Clinical significance of CD73 expression in triple-negative breast cancer from the BIG 02-98 adjuvant phase III clinical trial

10.1158/1538-7445.sabcs17-pd6-07 ◽

2018 ◽

Author(s):

L Buisseret ◽

S Pommey ◽

B Allard ◽

S Garaud ◽

MA Bergeron ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Clinical Significance ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Iii ◽

Phase Iii Clinical Trial ◽

Cd73 Expression

Download Full-text

Abstract P2-16-09: Residual cancer burden in patients with early stage triple negative breast cancer who progress on anthracycline-based neoadjuvant chemotherapy in an ongoing clinical trial (ARTEMIS)

10.1158/1538-7445.sabcs19-p2-16-09 ◽

2020 ◽

Author(s):

Haven Garber ◽

Gaiane Rauch ◽

Beatriz Adrada ◽

Rosalind Candelaria ◽

Elizabeth Mittendorf ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Neoadjuvant Chemotherapy ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Early Stage ◽

Ongoing Clinical Trial ◽

Residual Cancer ◽

Cancer Burden ◽

Residual Cancer Burden

Download Full-text

A novel RAF/MEK inhibitor CH5126766 in phase I clinical trial has an effectiveness in the combination with eribulin for the treatment of triple negative breast cancer

Annals of Oncology ◽

10.1093/annonc/mdz268.067 ◽

2019 ◽

Vol 30 ◽

pp. v782

Author(s):

H. Ono ◽

M. Horinaka ◽

S. Yasuda ◽

M. Morita ◽

E. Nishimoto ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Phase I ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Mek Inhibitor ◽

Phase I Clinical Trial

Download Full-text